» Authors » Jan-Erik Frodin

Jan-Erik Frodin

Explore the profile of Jan-Erik Frodin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 40
Citations 441
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
21.
Liljefors M, Nilsson B, Mellstedt H, Frodin J
Cancer Immunol Immunother . 2007 Aug; 57(3):379-88. PMID: 17676322
Recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) is used in immunotherapy for correction of neutropoenia. The optimal dose for activation of immune functions and the pharmacokinetics following repeated administrations is less analysed...
22.
Liljefors M, Nilsson B, Fagerberg J, Ragnhammar P, Mellstedt H, Frodin J
Int J Oncol . 2005 May; 26(6):1581-9. PMID: 15870873
The EpCAM antigen is highly expressed on colorectal carcinoma (CRC) cells. Murine anti-EpCAM MAb (anti-EpCAM mMAb) alone or in combination with cytokines may induce clinical responses including long-lasting complete remissions...
23.
Mosolits S, Markovic K, Fagerberg J, Frodin J, Rezvany M, Kiaii S, et al.
Cancer Immunol Immunother . 2004 Dec; 54(6):557-70. PMID: 15570423
The tumour-associated antigen, Ep-CAM, is over-expressed in colorectal carcinoma (CRC). In the present study, a recombinant Ep-CAM protein or a human anti-idiotypic antibody (anti-Id) mimicking Ep-CAM, either alone or in...
24.
Shetye J, Liljefors M, Emdin S, Frodin J, Strigard K, Mellstedt H, et al.
Anticancer Res . 2004 Aug; 24(4):2375-83. PMID: 15330187
Background: Bone marrow micrometastases (BMM) is considered to be of interest as a prognostic marker in solid tumors. The use of density-gradient separated bone marrow (BM) aspirates does not allow...
25.
Mosolits S, Markovic K, Frodin J, Virving L, Magnusson C, Steinitz M, et al.
Clin Cancer Res . 2004 Aug; 10(16):5391-402. PMID: 15328177
Purpose: The tumor-associated antigen Ep-CAM (epithelial cell adhesion molecule) is overexpressed in colorectal carcinoma (CRC). The aim of the present study was to evaluate and compare the safety and immunogenicity...
26.
Liljefors M, Ragnhammar P, Nilsson B, Ullenhag G, Mellstedt H, Frodin J
Int J Oncol . 2004 Aug; 25(3):703-11. PMID: 15289873
Monoclonal antibodies (MAbs) have different modes of action and toxicity profile compared to chemotherapeutics, which makes it interesting to combine these drugs. Addition of cytokines to MAb therapy may also...
27.
Ullenhag G, Frodin J, Jeddi-Tehrani M, Lidstromer N, Strigard K, Eriksson E, et al.
Clin Cancer Res . 2004 May; 10(10):3273-81. PMID: 15161680
Purpose: Previous studies have indicated that carcinoembryonic antigen (CEA) might be a suitable immunotherapeutic target in colorectal carcinoma (CRC). The aim of the present study was to analyze the immunological...
28.
Ullenhag G, Fagerberg J, Strigard K, Frodin J, Mellstedt H
Cancer Immunol Immunother . 2003 Nov; 53(4):331-7. PMID: 14605762
A baculovirus-produced recombinant CEA (rCEA) protein comprising the extracellular region was used for vaccination of CRC patients with or without GM-CSF as an adjuvant cytokine. Ten patients with a significant...
29.
Lindholm C, Cavallin-Stahl E, Ceberg J, Frodin J, Littbrand B, Moller T
Acta Oncol . 2003 Nov; 42(5-6):416-29. PMID: 14596504
A systematic assessment of radiotherapy for cancer was conducted by The Swedish Council on Technology Assessment in Health Care (SBU) in 2001. The assessment included a critical review of the...
30.
Moller T, Brorsson B, Ceberg J, Frodin J, Lindholm C, Nylen U, et al.
Acta Oncol . 2003 Nov; 42(5-6):387-410. PMID: 14596502
A prospective survey of radiotherapy practice in Sweden was conducted during 12 weeks in the autumn of 2001. All hospitals that provided radiotherapy participated, and all patients who started radiotherapy...